| Robert Klym, MD | |
|
807 N Justice St, Hendersonville, NC 28791-3409 | |
| (828) 693-0294 | |
| (828) 697-5738 |
| Full Name | Robert Klym |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 36 Years |
| Location | 807 N Justice St, Hendersonville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790764884 | NPI | - | NPPES |
| 2551788 | Medicaid | OH | |
| P00219240 | Other | OH | RR MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Waterloo Medical Center | Waterloo, IA | Hospital |
| Genesis Hospital | Zanesville, OH | Hospital |
| Sartori Memorial Hospital, Inc | Cedar falls, IA | Hospital |
| Knox Community Hospital | Mount vernon, OH | Hospital |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lucidsolutions Inc | 0749603462 | 65 |
| Riverside Radiology And Interventional Associates Inc | 8729976964 | 206 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses - the connection points between neurons - are repaired to keep communication between neurons at an optimal level.
A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.
› Verified 4 days ago
| Entity Name | Hendersonville Radiological Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538106810 PECOS PAC ID: 9032192414 Enrollment ID: O20040608000526 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses - the connection points between neurons - are repaired to keep communication between neurons at an optimal level.
A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.
› Verified 4 days ago
| Entity Name | Riverside Radiology And Interventional Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093718496 PECOS PAC ID: 8729976964 Enrollment ID: O20190320000422 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses - the connection points between neurons - are repaired to keep communication between neurons at an optimal level.
A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.
› Verified 4 days ago
| Entity Name | Lucidsolutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518594480 PECOS PAC ID: 0749603462 Enrollment ID: O20210601001839 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses - the connection points between neurons - are repaired to keep communication between neurons at an optimal level.
A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Klym, MD 807 N Justice St, Hendersonville, NC 28791-3409 Ph: (828) 693-0294 | Robert Klym, MD 807 N Justice St, Hendersonville, NC 28791-3409 Ph: (828) 693-0294 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses - the connection points between neurons - are repaired to keep communication between neurons at an optimal level.
A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.
› Verified 4 days ago
Devon Jacob Cole, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 807 N Justice St, Hendersonville, NC 28791 Phone: 828-693-0294 | |
Madeera Kathpal, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 805 6th Ave W Ste 100, Hendersonville, NC 28739 Phone: 828-696-1330 Fax: 828-696-1075 | |
Albert Iosue, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 558 Fleming St, Hendersonville, NC 28739 Phone: 828-692-6848 | |
John Mckay, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 N Justice St, Hendersonville, NC 28791 Phone: 843-467-2676 Fax: 843-497-9566 | |
Elwood E. Stone, M. D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 807 N Justice St, Hendersonville, NC 28791 Phone: 828-693-0294 Fax: 828-697-5738 | |
Leroy George Hoffman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 805 6th Ave W Ste 100, Hendersonville, NC 28739 Phone: 828-692-8045 Fax: 828-692-6630 |